The nice people at “Transfusion News” sent their update today. Perhaps not as useful as some of their output… but all good stuff.
May 24, 2022[Read More]Chimeric antigen receptor (CAR) T-cell therapy is a promising therapy used to treat hematological cancers by targeting a specific antigen. Notably, CD19 CAR T-cell therapy has a 90% complete response rate in children and adults with acute lymphoblastic leukemia (ALL), but it is unclear why about 10% of patients do not respond to treatment.
Join Transfusion News Associate Editors Daniela Hermelin MD and Monica Pagano MD on Friday May 27 from 11:00-11:30 AM EST for the next #Blooducation Baristas live event. Dr. Heremlin and Dr. Pagano will be joined by Dr. José Arnulfo Pérez-Carrillo, Dra. Silvina Kuperman and Dr. Hector Baptista for our first event en español. [Set a reminder to join us]
May 17, 2022 [Read More]Allergic transfusion reactions (ATRs) are common and can range from mild to severe. Younger age, hematological/oncological disease, increasing number of transfusions, and past history of ATRs are all risk factors for ATRs. Although the exact mechanism for ATRs is not well understood, type I immunoglobulin E (IgE)-mediated hypersensitivity and/or basophils are likely involved.